StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report released on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Down 3.2 %
NASDAQ:LPCN opened at $4.85 on Friday. The stock has a fifty day simple moving average of $4.71 and a 200 day simple moving average of $3.68. The firm has a market capitalization of $25.94 million, a price-to-earnings ratio of -1.59 and a beta of 1.11. Lipocine has a 1-year low of $2.31 and a 1-year high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $0.22 million during the quarter. Equities analysts predict that Lipocine will post -1.49 earnings per share for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Recommended Stories
- Five stocks we like better than Lipocine
- What is a Low P/E Ratio and What Does it Tell Investors?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- NYSE Stocks Give Investors a Variety of Quality Options
- Generac Powers Ahead on the Electrification Mega-Trend
- Insider Selling Explained: Can it Inform Your Investing Choices?
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}
